Arcturus Therapeutics Announces Initiation of Phase 1 H5N1 Flu Vaccine Trial
Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a commercial messenger RNA medicines company focused on the development of infectious disease vaccines and opportunities within liver and respiratory rare diseases, today …